Heron Therapeutics, Inc.
HRTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 13.6% | 18% | 24.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 73.2% | 48.8% | 49% | 46.7% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3.5% | -81.7% | -164.1% | -249.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -9.4% | -87% | -169.1% | -255.6% |
| EPS Diluted | -0.089 | -0.8 | -1.67 | -2.24 |
| % Growth | 88.9% | 52.1% | 25.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |